18931-61-8

Basic information

• Product Name: 1-(4-BROMO-PHENYL)-4,4,4-TRIFLUORO-BUTANE-1,3-DIONE
• Synonyms: ART-CHEM-BB B007343;AKOS B007343;AKOS MSC-0335;1-(4-BROMO-PHENYL)-4,4,4-TRIFLUORO-BUTANE-1,3-DIONE;1-(4-Bromo-phenyl)-4,4,4-trifluoro-butane-1,3-;1-(4-BroMophenyl)-4,4,4-trifluoro-1,3-butanedione
• CAS NO: 18931-61-8
• Molecular Formula: C₁₀H₆BrF₃O₂
• Molecular Weight: 295.05
• Mol File: 18931-61-8.mol
• Article Data: 19

Chemical Properties

• Melting Point: 53-55°C
• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1-(4-BROMO-PHENYL)-4,4,4-TRIFLUORO-BUTANE-1,3-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-BROMO-PHENYL)-4,4,4-TRIFLUORO-BUTANE-1,3-DIONE(18931-61-8)
• EPA Substance Registry System: 1-(4-BROMO-PHENYL)-4,4,4-TRIFLUORO-BUTANE-1,3-DIONE(18931-61-8)

Safety Data

• Hazardous Substances Data: 18931-61-8(Hazardous Substances Data)

Usage

General Description

1-(4-Bromo-phenyl)-4,4,4-trifluoro-butane-1,3-dione is a chemical compound with the molecular formula C10H6BrF3O2. It is a derivative of 1,3-diketone and contains a bromo-phenyl group as well as three trifluoromethyl groups. 1-(4-BROMO-PHENYL)-4,4,4-TRIFLUORO-BUTANE-1,3-DIONE is often used in organic synthesis and pharmaceutical research due to its unique structure and potential applications. It has been studied for its potential as a building block in the synthesis of various pharmaceutical compounds and as a reagent in organic reactions. Additionally, its trifluoromethyl groups make it a potentially valuable molecule in the development of fluorinated organic compounds, which have diverse applications in medicinal chemistry and materials science.

Upstream product

• 431-47-0 trifluoroacetic acid-methyl ester 
• 99-90-1 para-bromoacetophenone 
• 1546-79-8 N-trifluoroacetylimidazole 
• 383-63-1 ethyl trifluoroacetate, 

Downstream Products

• 586333-33-7 1-phenyl-3-(trifluoromethyl)-5-(4-bromophenyl)-1H-pyrazole 
• 252561-06-1 4,4,4-trifluoro-1-[4-(furan-2-yl)phenyl]butane-1,3-dione 
• 1352406-65-5 (4-bromophenyl)[1-(4-chlorophenyl)-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl]methanone 

Relevant articles and documents

N-(3-((4-trifluoromethyl)-2-pyrimidinyl)aminophenyl)-2,6-difluorobenzene sulfamide derivative

The invention discloses N-(3-((4-trifluoromethyl)-2-pyrimidinyl)aminophenyl)-2,6-difluorobenzene sulfamide having an anti-tumor activity and a derivative thereof, and synthesis methods thereof. The N-(3-((4-trifluoromethyl)-2-pyrimidinyl)aminophenyl)-2,6-difluorobenzene sulfamide has a structural formula as shown in Formula I. The synthesis method disclosed by the invention comprises the followingsteps: performing nucleophilic substitution on 2,6-difluorobenzenesulfonyl chloride and m-phenylenediamine to obtain sulfonamide; enabling an amino group of N-(3-aminophenyl)-2,6-difluorobenzene sulfamide to react with cyanamide to obtain guanidine salt; then preparing a series of different substituted 1,3-diketone compounds; finally, enabling the guanidine salt to react with 1,3-diketone to forma pyrimidine ring, and ingeniously introducing the anactive group of the pyrimidine ring into a molecular structure. According to the N-(3-((4-trifluoromethyl)-2-pyrimidinyl)aminophenyl)-2,6-difluorobenzene sulfamide and the synthesis method, the antitumor multiplication inhibition activity, the solubility and the like of a compound is adjusted by changing a substituent of the pyrimidine ring, and the compound has the advantage of simple and convenient adjustment.

Design and synthesis of novel benzenesulfonamide containing 1,2,3-triazoles as potent human carbonic anhydrase isoforms I, II, IV and IX inhibitors

In a quest to discover new biologically active compounds, a series of twenty novel heterocyclic derivatives substituted at position 5 with -H (7a-7j) or -CF3 (8a-8j), bearing benzenesulfonamide at N-1 position and various aroyl groups at position 4 of the 1,2,3-triazole ring was synthesized and screened for their carbonic anhydrase (CA, EC 4.2.1.1) inhibition potential against four human (h) isoforms hCA I, II, IV and IX. All the compounds (7a-7j and 8a-8j) were synthesized via [3+2] cycloaddition reaction from 4-azidobenzenesulfonamide. Interestingly, compounds 7a-7j were prepared in one pot manner via enaminone intermediate using novel methodology. All the newly synthesized compounds (7a-7j & 8a-8j) were found to be excellent inhibitors of edema related isoform hCA I with their inhibition constant (Ki) ranging from 30.1 to 86.8 nM as compared to standard drug acetazolamide (AAZ) with Ki = 250 nM. Further it was found that most of tested compounds were weaker inhibitors of isoform, hCA II although compounds 7b, 7d-7e, 8a, 8d-8f, 8i (mostly with electron withdrawing substituents) have shown better inhibition potential (Ki i = 52.4 nM) than AAZ (Ki = 74 nM) while against tumor associated hCA IX, all the compounds have shown moderate inhibition potential. Present study have added one more step in exploring the 1,2,3-triazlole moiety in the medicinal field.

Oxygen Activated, Palladium Nanoparticle Catalyzed, Ultrafast Cross-Coupling of Organolithium Reagents

The discovery of an ultrafast cross-coupling of alkyl- and aryllithium reagents with a range of aryl bromides is presented. The essential role of molecular oxygen to form the active palladium catalyst was established; palladium nanoparticles that are highly active in cross-coupling reactions with reaction times ranging from 5 s to 5 min are thus generated in situ. High selectivities were observed for a range of heterocycles and functional groups as well as for an expanded scope of organolithium reagents. The applicability of this method was showcased by the synthesis of the [11C]-labeled PET tracer celecoxib.